RESPIRATORY RECURRENT PAPILLOMATOSIS (RRP)

Clinical trials for RESPIRATORY RECURRENT PAPILLOMATOSIS (RRP) explained in plain language.

Never miss a new study

Get alerted when new RESPIRATORY RECURRENT PAPILLOMATOSIS (RRP) trials appear

Sign up with your email to follow new studies for RESPIRATORY RECURRENT PAPILLOMATOSIS (RRP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can a vaccine plus a Blood-Vessel blocker stop airway growths from coming back?

Disease control Not yet recruiting

This phase II trial tests whether combining bevacizumab, a drug that limits blood vessel growth, with PRGN-2012, a vaccine-based therapy, can help adults with recurrent respiratory papillomatosis (RRP) avoid needing more surgeries. RRP causes wart-like growths in the airway that …

Matched conditions: RESPIRATORY RECURRENT PAPILLOMATOSIS (RRP)

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Aug 16, 2026 00:00 UTC

RESPIRATORY RECURRENT PAPILLOMATOSIS (RRP)

Get alerted when new RESPIRATORY RECURRENT PAPILLOMATOSIS (RRP) trials appear

Can a vaccine plus a Blood-Vessel blocker stop airway growths from coming back?